PMID- 28699796
OWN - NLM
STAT- MEDLINE
DCOM- 20180501
LR  - 20181202
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 33
IP  - 12
DP  - 2017 Dec
TI  - Utilization and safety of proton-pump inhibitors and histamine-2 receptor 
      antagonists in children and adolescents: an observational cohort study.
PG  - 2201-2209
LID - 10.1080/03007995.2017.1354830 [doi]
AB  - BACKGROUND: Little is known about the use of acid-suppressing treatments and 
      related safety events in children. OBJECTIVE: This study compared patient 
      characteristics and safety outcomes among children prescribed acid-suppressing 
      drugs for the first time. METHODS: The Health Improvement Network was used to 
      determine the characteristics of children prescribed a proton pump inhibitor 
      (PPI; esomeprazole or another PPI) or a histamine-2 receptor antagonist (H(2)RA) 
      by UK primary care physicians between October 2009 and September 2012. 
      Pre-defined safety outcomes were compared among the treatment groups in up to 18 
      months of follow-up. RESULTS: The cohorts comprised 8,172 patients on PPIs 
      (including 24 patients on esomeprazole) and 7,905 on H(2)RAs. The baseline 
      characteristics were similar between cohorts, although the children in the PPI 
      cohorts tended to be older. No safety outcomes occurred in the esomeprazole 
      cohort. In the other-PPIs cohort, 92 safety outcomes occurred, most commonly 
      gastroenteritis (n = 36; 39.1%). In the H(2)RAs cohort, 193 safety outcomes 
      occurred, most commonly gastroenteritis (n = 62; 32.1%). The incidence of most 
      safety outcomes was higher in the H(2)RAs cohort than in the other-PPIs cohort, 
      including failure to thrive (3.11 [95% confidence interval (CI) = 2.25-4.28] vs 
      0.49 per 1,000 person-years [95% CI = 0.22-1.07]) and gastroenteritis (5.27 [95% 
      CI = 4.11-6.75] vs 3.04 per 1,000 person-years [95% CI = 2.20-4.20]). CONCLUSION: 
      Esomeprazole is rarely prescribed to children when they first require 
      acid-suppressing medication, compared with other PPIs/H(2)RAs. Overall, more 
      safety outcomes occurred in the H(2)RAs cohort than in the PPI cohorts.
FAU - Ruigomez, A
AU  - Ruigomez A
AD  - a Spanish Centre for Pharmacoepidemiologic Research (CEIFE) , Madrid , Spain.
FAU - Johansson, S
AU  - Johansson S
AD  - b AstraZeneca Gothenburg , Molndal , Sweden.
FAU - Nagy, P
AU  - Nagy P
AD  - c Former employee of AstraZeneca Gothenburg , Molndal , Sweden.
FAU - Garcia Rodriguez, L A
AU  - Garcia Rodriguez LA
AD  - a Spanish Centre for Pharmacoepidemiologic Research (CEIFE) , Madrid , Spain.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20170721
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Histamine H2 Antagonists)
RN  - 0 (Proton Pump Inhibitors)
RN  - N3PA6559FT (Esomeprazole)
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Child, Preschool
MH  - Cohort Studies
MH  - Esomeprazole/*therapeutic use
MH  - Female
MH  - Histamine H2 Antagonists/*therapeutic use
MH  - Humans
MH  - Incidence
MH  - Infant
MH  - Male
MH  - Proton Pump Inhibitors/*therapeutic use
OTO - NOTNLM
OT  - Acid-suppressing drugs
OT  - The Health Improvement Network (THIN)
OT  - children
OT  - drug safety
OT  - gastroesophageal reflux disease
OT  - pharmacoepidemiology
EDAT- 2017/07/13 06:00
MHDA- 2018/05/02 06:00
CRDT- 2017/07/13 06:00
PHST- 2017/07/13 06:00 [pubmed]
PHST- 2018/05/02 06:00 [medline]
PHST- 2017/07/13 06:00 [entrez]
AID - 10.1080/03007995.2017.1354830 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2017 Dec;33(12):2201-2209. doi: 10.1080/03007995.2017.1354830. 
      Epub 2017 Jul 21.